SLC2A1 and neoplasm: We accomplished this goal by orthogonally targeting transferrin (Tf) receptor12 and glucose transporter (GLUT-1)24 expressed on tumor cells with TiO2-TC-Tf and the radiopharmaceutical 18FDG, respectively.